ID

21764

Descrição

Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.; ODM derived from: https://clinicaltrials.gov/show/NCT00770952

Link

https://clinicaltrials.gov/show/NCT00770952

Palavras-chave

Versões (1)
  1. 29/04/2017 29/04/2017 -
Transferido a

29 de abril de 2017

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Diabetes Mellitus NCT00770952

Inglês

Eligibility Diabetes Mellitus NCT00770952

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes according to the american diabetes association criteria.
Descrição

diabetes mellitus type 2

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0011860
treatment with glimepiride monotherapy (1-3 mg per day) 3 months before entering the study.
Descrição

glimepiride

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0061323
glycosylated hemoglobin greater than 6.5%, but less than 8.5% and/ or fasting plasma glucose greater than 7 mmol/l within the last 4 weeks.
Descrição

HbA1c, fasting plasma glucose

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0019018
UMLS CUI [2]
C0583513
females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from screening throughout the duration of the study.
Descrição

pregnancy, breast feeding, contraception

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0700589
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
type 1 diabetes mellitus.
Descrição

diabetes mellitus type 1

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0011854
history of hypersensitivity to the study drugs or to drugs with similar chemical structures.
Descrição

drug hypersensitivity

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0013182
progressive fatal disease.
Descrição

progressive fatal diseases

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0205082
UMLS CUI [1,2]
C1335499
history of drug or alcohol abuse during the last 5 years.
Descrição

drug or alcohol abuse

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0038586
more than one unexplained episode of severe hypoglycemia within 6 months prior to entering the study.
Descrição

severe hypoglycemia

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0020615
UMLS CUI [1,2]
C0205082
a history of significant cardiovascular (new york heart association stage i - iv), respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.8 mg/dl; glomerular filtration rate less than 40 ml/min as estimated by the cockroft-gault formula), neurological, psychiatric and/or hematological disease, history of macular edema.
Descrição

cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric or hematological disease, macular edema

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C1275491
UMLS CUI [2]
C0035204
UMLS CUI [3]
C0017178
UMLS CUI [4,1]
C0023895
UMLS CUI [4,2]
C0201836
UMLS CUI [5,1]
C0022658
UMLS CUI [5,2]
C0201976
UMLS CUI [5,3]
C0017654
UMLS CUI [5,4]
C4064204
UMLS CUI [6]
C0027765
UMLS CUI [7]
C0004936
UMLS CUI [8]
C0018939
UMLS CUI [9]
C0271051
blood donation within the last 30 days.
Descrição

blood donation

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0005794
is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
Descrição

medication or herbal treatment interfere with drug evaluation

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1360419
UMLS CUI [1,3]
C0521102
UMLS CUI [1,4]
C0013175
cyp2c9 inductors
Descrição

cyp2c9 inducers

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3850046
cyp2c9 inhibitors
Descrição

cyp2c9 inhibitors

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3850060
rifampicin
Descrição

rifampicin

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0035608
fluconazole
Descrição

fluconazole

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0016277
drugs used for treating type 2 diabetes (insulin, insulin analogous compounds and oral antidiabetic drugs)
Descrição

diabetes mellitus type 2 drugs

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0013227
pretreatment with thiazolidinediones within the last 12 months.
Descrição

thiazolidinediones

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1257987
Voltar ao início da página

Similar models

Eligibility Diabetes Mellitus NCT00770952

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
diabetes mellitus type 2
Item
type 2 diabetes according to the american diabetes association criteria.
boolean
C0011860 (UMLS CUI [1])
glimepiride
Item
treatment with glimepiride monotherapy (1-3 mg per day) 3 months before entering the study.
boolean
C0061323 (UMLS CUI [1])
HbA1c, fasting plasma glucose
Item
glycosylated hemoglobin greater than 6.5%, but less than 8.5% and/ or fasting plasma glucose greater than 7 mmol/l within the last 4 weeks.
boolean
C0019018 (UMLS CUI [1])
C0583513 (UMLS CUI [2])
pregnancy, breast feeding, contraception
Item
females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from screening throughout the duration of the study.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
diabetes mellitus type 1
Item
type 1 diabetes mellitus.
boolean
C0011854 (UMLS CUI [1])
drug hypersensitivity
Item
history of hypersensitivity to the study drugs or to drugs with similar chemical structures.
boolean
C0013182 (UMLS CUI [1])
progressive fatal diseases
Item
progressive fatal disease.
boolean
C0205082 (UMLS CUI [1,1])
C1335499 (UMLS CUI [1,2])
drug or alcohol abuse
Item
history of drug or alcohol abuse during the last 5 years.
boolean
C0038586 (UMLS CUI [1])
severe hypoglycemia
Item
more than one unexplained episode of severe hypoglycemia within 6 months prior to entering the study.
boolean
C0020615 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric or hematological disease, macular edema
Item
a history of significant cardiovascular (new york heart association stage i - iv), respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.8 mg/dl; glomerular filtration rate less than 40 ml/min as estimated by the cockroft-gault formula), neurological, psychiatric and/or hematological disease, history of macular edema.
boolean
C0007222 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C0035204 (UMLS CUI [2])
C0017178 (UMLS CUI [3])
C0023895 (UMLS CUI [4,1])
C0201836 (UMLS CUI [4,2])
C0022658 (UMLS CUI [5,1])
C0201976 (UMLS CUI [5,2])
C0017654 (UMLS CUI [5,3])
C4064204 (UMLS CUI [5,4])
C0027765 (UMLS CUI [6])
C0004936 (UMLS CUI [7])
C0018939 (UMLS CUI [8])
C0271051 (UMLS CUI [9])
blood donation
Item
blood donation within the last 30 days.
boolean
C0005794 (UMLS CUI [1])
medication or herbal treatment interfere with drug evaluation
Item
is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
boolean
C0013227 (UMLS CUI [1,1])
C1360419 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0013175 (UMLS CUI [1,4])
cyp2c9 inducers
Item
cyp2c9 inductors
boolean
C3850046 (UMLS CUI [1])
cyp2c9 inhibitors
Item
cyp2c9 inhibitors
boolean
C3850060 (UMLS CUI [1])
rifampicin
Item
rifampicin
boolean
C0035608 (UMLS CUI [1])
fluconazole
Item
fluconazole
boolean
C0016277 (UMLS CUI [1])
diabetes mellitus type 2 drugs
Item
drugs used for treating type 2 diabetes (insulin, insulin analogous compounds and oral antidiabetic drugs)
boolean
C0011860 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
thiazolidinediones
Item
pretreatment with thiazolidinediones within the last 12 months.
boolean
C1257987 (UMLS CUI [1])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial